Regeneron Pharmaceuticals, Inc. (REGN)
NASDAQ · Healthcare · Biotechnology
Profile
Regeneron Pharmaceuticals, Inc.
- Exchange
- NASDAQ
- Ticker
- REGN
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- US
Regeneron Pharmaceuticals, Inc. is a global biopharmaceutical enterprise focused on discovering, inventing, developing, manufacturing, and bringing to market medical treatments for a wide array of illnesses. Its therapeutic portfolio includes EYLEA, an injection used to treat various ophthalmic conditions such as wet age-related macular degeneration, diabetic macular edema, myopic choroidal neovascularization, diabetic retinopathy, and macular edema resulting from retinal vein occlusion (both central and branch). Other significant offerings are Dupixent, an injectable solution for atopic dermatitis and asthma in both adults and pediatric patients; Libtayo, indicated for metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent, an injection prescribed for adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease; REGEN-COV for COVID-19; and Kevzara, a solution targeting rheumatoid arthritis in adult patients. Furthermore, Regeneron provides Inmazeb for infections caused by Zaire ebolavirus; ARCALYST, an injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and Muckle-Wells syndrome; and ZALTRAP, an intravenous infusion used in the treatment of metastatic colorectal cancer. In addition to its existing product lineup, the company is actively engaged in developing novel product candidates aimed at addressing unmet medical needs in areas such as ocular diseases, allergic and inflammatory conditions, cardiovascular and metabolic disorders, infectious diseases, rare diseases, cancer, pain management, and hematologic conditions. Regeneron maintains extensive collaboration and licensing agreements with a diverse range of partners, including Sanofi, Bayer, Teva Pharmaceutical Industries Ltd., Mitsubishi Tanabe Pharma Corporation, Alnylam Pharmaceuticals, Inc., Roche Pharmaceuticals, and Kiniksa Pharmaceuticals, Ltd. It also holds agreements with entities such as the U.S. Department of Health and Human Services, Zai Lab Limited, Intellia Therapeutics, Inc., the Biomedical Advanced Research Development Authority, and AstraZeneca PLC. The company was founded in 1988 and its corporate headquarters are situated in Tarrytown, New York.
Key facts
Regeneron Pharmaceuticals, Inc.: key facts
- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) is a Biotechnology company in the Healthcare sector.
- In fiscal 2025, Regeneron Pharmaceuticals, Inc. reported revenue of $14.3B and net income of $4.5B.
- Revenue fell 2.8% a year over the last 4 fiscal years.
- Free cash flow was positive in 5 of the last 5 fiscal years.
- Net income was positive in 5 of the last 5 fiscal years.
- Over the last twelve months, revenue was $16.9B and net income was $4.8B.
MonkScore
Regeneron Pharmaceuticals, Inc.'s MonkScore
MonkScore
MonkScore range: 30–40
as of October 2026
Sector rank: 465 of 628 in Healthcare
How this score is madeDisclaimer
Pillar ranges
- Growth30–40
- Profitability80–90
- Quality40–50
- Market Conviction30–40
- Safety40–50
The MonkScore runs from 0 to 100. Each range is one of ten 10-point groups, from 0–10 to 90–100.
Each pillar's range uses the same ten groups. The exact score and the pillar scores are in the MonkStreet app.
Fundamentals
Figures from the statements
Regeneron Pharmaceuticals, Inc.'s annual figures and the last twelve months, in USD. Last report: 30 September 2026.
| Figure | Last 12 months | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Revenue | $16.9B | $14.3B | $14.2B | $13.1B | $12.2B | $16.1B |
| Gross profit | $14.5B | $12.2B | $12.2B | $10.9B | $10.5B | $13.3B |
| Operating income | $5.0B | $3.6B | $4.0B | $4.3B | $5.4B | $8.9B |
| Net income | $4.8B | $4.5B | $4.4B | $4.0B | $4.3B | $8.1B |
| Operating cash flow | $4.6B | $5.0B | $4.4B | $4.6B | $5.0B | $7.1B |
| Capital expenditure | -$1.0B | -$898.4M | -$755.9M | -$926.4M | -$590.1M | -$551.9M |
| Free cash flow | $3.6B | $4.1B | $3.7B | $3.7B | $4.4B | $6.5B |
| Total debt | $2.7B | $2.7B | $2.7B | $2.7B | $2.7B | $2.7B |
| Cash | $3.7B | $3.1B | $2.5B | $2.7B | $3.1B | $2.9B |
Revenue growth a year
- 1-year
- 1.0%
- 3-year
- 5.6%
- 4-year
- -2.8%
Compound growth between fiscal years.
Peers
Similar companies
- Ionis Pharmaceuticals, Inc.NASDAQ:IONSMonkScore range: 30–40
- 4D Molecular Therapeutics, Inc.NASDAQ:FDMTMonkScore range: 30–40
- uniQure N.V.NASDAQ:QUREMonkScore range: 30–40
- Rigel Pharmaceuticals, Inc.NASDAQ:RIGLMonkScore range: 30–40
- Bio-Techne CorporationNASDAQ:TECHMonkScore range: 30–40
- Altimmune, Inc.NASDAQ:ALTMonkScore range: 40–50
- Zevra Therapeutics, Inc.NASDAQ:ZVRAMonkScore range: 40–50
- Arbutus Biopharma CorpNASDAQ:ABUSMonkScore range: 40–50
Score my top stocks · 14-day free trial · card required · not charged during the trial · cancel in one click
MonkStreet provides research, not investment advice.
Page built on 31 October 2026.